DOCSLIB.ORG

1 Activity of the Second Generation BTK Inhibitor Acalabrutinib In

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 Activity of the Second Generation BTK Inhibitor Acalabrutinib In Activity of the Second Generation BTK Inhibitor Acalabrutinib in Canine and Human B-cell Non-Hodgkin Lymphoma Dissertation Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Bonnie Kate Harrington Graduate Program in Comparative and Veterinary Medicine The Ohio State University 2018 Dissertation Committee John C. Byrd, M.D., Advisor Amy J. Johnson, Ph.D. Krista La Perle, D.V.M., Ph.D. William C. Kisseberth, D.V.M., Ph.D. 1 Copyrighted by Bonnie Kate Harrington 2018 2 Abstract Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton’s Tyrosine Kinase (BTK) with increased target selectivity and potency compared to ibrutinib. In these studies, we evaluated acalabrutinib in spontaneously occurring canine lymphoma, a model of B-cell malignancy reported to be similar to human diffuse large B-cell lymphoma (DLBCL), as well as primary human chronic lymphocytic leukemia (CLL) cells. We demonstrated that acalabrutinib potently inhibited BTK activity and downstream B-cell receptor (BCR) effectors in CLBL1, a canine B-cell lymphoma cell line, primary canine lymphoma cells, and primary CLL cells. Compared to ibrutinib, acalabrutinib is a more specific inhibitor and lacked off-target effects on the T-cell and NK cell kinase IL-2 inducible T-cell kinase (ITK) and epidermal growth factor receptor (EGFR). Accordingly, acalabrutinib did not antagonize antibody dependent cell cytotoxicity mediated by NK cells. Finally, acalabrutinib inhibited proliferation and viability in CLBL1 cells and primary CLL cells and abrogated chemotactic migration in primary CLL cells. To support our in vitro findings, we conducted a clinical trial using companion dogs with spontaneously occurring B-cell lymphoma. Twenty dogs were enrolled in the clinical trial and treated with acalabrutinib at dosages of 2.5 to 20mg/kg every 12 or 24 hours. Acalabrutinib was generally well tolerated, with ii adverse events consisting primarily of grade 1 or 2 anorexia, weight loss, vomiting, diarrhea and lethargy. Overall response rate (ORR) was 25% (5/20) with a median progression free survival (PFS) of 22.5 days. Clinical benefit was observed in 30% (6/20) of dogs. These findings suggest that acalabrutinib is safe and exhibits activity in canine B-cell lymphoma patients and support the use of canine lymphoma as a relevant model for human non-Hodgkin lymphoma (NHL). iii Dedication This work is dedicated to my father, Jeff Harrington, a survivor of both CLL and renal carcinoma; to my mother, Sandy Harrington; to my husband, Alan Flechtner; and to my son, Blaise Flechtner. Thank you for supporting me. iv Acknowledgments I would like to acknowledge my mentors Dr. John Byrd and Amy Johnson for providing the scholarly yet nurturing environment for my intellect to grow; the funding sources that provided my stipend during training, the National Institutes of Health Oncology T32 and the Pelotonia Graduate Fellowship; and all of those in the Experimental Hematology Lab or elsewhere that supported me in graduate school and contributed to my development as an independent investigator. v Vita December 27, 1984……………………………………….Born – North Canton, Ohio 2003……………..……………………..…………………………GlenOak High School 2007………………………………….…B.S. Psychology, The Ohio State University 2012……………………………..…………………D.V.M., The Ohio State University 2012-Present…………..………………Ph.D. Candidate, The Ohio State University PUBLICATIONS Ozer H.G., El-Gamal D., Ben Powell B., Hing Z.A., Blachly J.S., Harrington B.K., Mitchell S., Grieselhuber N.R.,Williams K., Lai T., Alinari L., Baiocchi R.A., Brinton L., Baskin E., Cannon M., Beaver L., Goettl, V.M., Lucas D.M., Woyach J.A., Sampath D., Lehman A.M., Yu L.,Zhang J., Ma Y., Zhang Y., Spevak W., Shi S., Severson P., Shellooe R., Carias H., Tsang G., Dong K., Ewing T., Marimuthu A., Tantoy C., Walters L., Sanftner L., Rezaei H., Nespi M., Matusow B., Habets G., Ibrahim P., Zhang C., Mathé1 E.A., Bollag G., Byrd J.C., Lapalombella R.(2018) BRD4 profiling identifies critical chronic lymphocytic leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor. Cancer Discov. 4, 458-477. vi Tsai Y.T., Lakshmanan A., Lehman A., Harrington B.K., McClanahan Lucas F., Tran M., Sass E.J., Long M., Flechtner A.D., Jaynes F., La Perle K., Coppola V., Lozanski G., Muthusamy N., Byrd J.C., Grever M., Lucas D.M. (2017) BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia. Blood Adv. 24, 2147-2160. Chen T.L., Tran M., Lakshmanan A., Harrington B.K., Goettl V.M., Lehman A.M., Trudeau S., Lucas D.M., Johnson A.J., Byrd J.C., Hertlein E. (2017). NF-κB p50 (nfkb1) contributes to pathogenesis in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia. Blood 130, 376-379. Herman S.E.M., Montraveta A., Niemann C.U., Mora-Jensen H., Gulrajani M., Krantz F., Mantel R., Smith L.L., McClanahan F., Harrington B.K., Colomer D., Covey T., Byrd J.C., Izumi R., Kaptein A., Ulrich R., Johnson A.J., Lannutti B.J., Wiestner A., Woyach J.A. (2017). The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. Clin. Cancer Res. 23, 2831-284. Harrington, B.K., Gardner, H.L., Izumi, R., Hamdy, A., Rothbaum, W., Coombes, K., Kaptein, A., Covery, T., Gulrajani, M., Van Lith, B., Krejsa, C., Russell, D., Zhang, X., Urie, B., London,C.A., Byrd, J.C., Johnson, A.J., Kisseberth, W.C. vii (2016). ACP-196: A second generation BTK inhibitor in a canine model of B-cell non-Hodgkin lymphoma. PLoS One. 11, 7. Byrd, J.C.*, Harrington, B.*, O’Brien, S., Jones, J.A., Schuh, A., Devereux, S., Chaves, J., Wierda, W.G., Awan, F.T., Brown, J.R., et al. (2016). Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med. 374, 323–332. * Indicates these authors contributed equally Stiff A., Trikha P., Wesolowski R., Kendra K., Hsu V., Uppati S., McMichael E., Duggan M, Campbell A, Keller K., Landi I., Zhong Y., Dubovsky J., Howard J.H., Yu L, Harrington B., Old M., Reiff S., Mace T., Tridandapani S., Muthusamy N., Caligiuri M.A., Byrd J.C., Carson W.E. 3rd. (2016). Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. Cancer Res. 76, 2125-2136. Coble, D.J., Shoemaker, M., Harrington, B., Dardenne, A.D., and Bolon, B. (2015). Histiocytic Sarcoma and Bilateral Facial Vein Thrombosis in a Siberian Hamster (Phodopus sungorus). Comp. Med. 65, 127–132. Dubovsky, J.A., Flynn, R., Du, J., Harrington, B.K., Zhong, Y., Kaffenberger, B., Yang, C., Towns, W.H., Lehman, A., Johnson, A.J., et al. (2014). Ibrutinib viii treatment ameliorates murine chronic graft-versus-host disease. J. Clin. Invest. 124, 4867–4876. Woyach, J.A., Bojnik, E., Ruppert, A.S., Stefanovski, M.R., Goettl, V.M., Smucker, K.A., Smith, L.L., Dubovsky, J.A., Towns, W.H., MacMurray, J., Harrington, B.K. et al. (2014). Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood 123, 1207–1213. Fenger, J.M., Bear, M.D., Volinia, S., Lin, T.-Y., Harrington, B.K., London, C.A., and Kisseberth, W.C. (2014). Overexpression of miR-9 in mast cells is associated with invasive behavior and spontaneous metastasis. BMC Cancer 14, 84. Zhong, Y., El-Gamal, D., Dubovsky, J.A., Beckwith, K.A., Harrington, B.K., Williams, K.E., Goettl, V.M., Jha, S., Mo, X., Jones, J.A., et al. (2014). Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells. Leukemia 28, 1158–1163. Dubovsky, J.A., Chappell, D.L., Harrington, B.K., Agrawal, K., Andritsos, L.A., Flynn, J.M., Jones, J.A., Paulaitis, M.E., Bolon, B., Johnson, A.J., et al. (2013). ix Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane- associated antigen critical to niche homing. Blood 122, 3308–3316. Fields of Study Major Field: Comparative and Veterinary Medicine x Table of Contents Abstract .......................................................................................................................ii Dedication ..................................................................................................................iv Acknowledgments ..................................................................................................... v Vita .............................................................................................................................vi Table of Contents ......................................................................................................xi List of Tables............................................................................................................ xiii List of Figures .......................................................................................................... xiv Chapter 1. Introduction.............................................................................................. 1 1.1 Chronic Lymphocytic Leukemia ...................................................................... 1 1.2 Traditional Therapies for Lymphoid Malignancies ......................................... 3 1.3 Targeting Bruton’s Tyrosine Kinase (BTK) in B-cell Malignancies ............... 4 1.4 Exploiting Canine Lymphoma as a Model for Human Disease..................... 6 Chapter 2. Preclinical Evaluation of the Novel BTK Inhibitor
Load more

Recommended publications
  • Proteomics and Drug Repurposing in CLL Towards Precision Medicine
    cancers Review Proteomics and Drug Repurposing in CLL towards Precision Medicine Dimitra Mavridou 1,2,3, Konstantina Psatha 1,2,3,4,* and Michalis Aivaliotis 1,2,3,4,* 1 Laboratory of Biochemistry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece; [email protected] 2 Functional Proteomics and Systems Biology (FunPATh)—Center for Interdisciplinary Research and Innovation (CIRI-AUTH), GR-57001 Thessaloniki, Greece 3 Basic and Translational Research Unit, Special Unit for Biomedical Research and Education, School of Medicine, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece 4 Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology, GR-70013 Heraklion, Greece * Correspondence: [email protected] (K.P.); [email protected] (M.A.) Simple Summary: Despite continued efforts, the current status of knowledge in CLL molecular pathobiology, diagnosis, prognosis and treatment remains elusive and imprecise. Proteomics ap- proaches combined with advanced bioinformatics and drug repurposing promise to shed light on the complex proteome heterogeneity of CLL patients and mitigate, improve, or even eliminate the knowledge stagnation. In relation to this concept, this review presents a brief overview of all the available proteomics and drug repurposing studies in CLL and suggests the way such studies can be exploited to find effective therapeutic options combined with drug repurposing strategies to adopt and accost a more “precision medicine” spectrum. Citation: Mavridou, D.; Psatha, K.; Abstract: CLL is a hematological malignancy considered as the most frequent lymphoproliferative Aivaliotis, M. Proteomics and Drug disease in the western world. It is characterized by high molecular heterogeneity and despite the Repurposing in CLL towards available therapeutic options, there are many patient subgroups showing the insufficient effectiveness Precision Medicine.
    [Show full text]
  • Inhibitors Targeting Bruton’S Tyrosine Kinase in Cancers
    Leukemia (2021) 35:312–332 https://doi.org/10.1038/s41375-020-01072-6 REVIEW ARTICLE Lymphoma Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances 1 2 1 2 1 Tingyu Wen ● Jinsong Wang ● Yuankai Shi ● Haili Qian ● Peng Liu Received: 2 April 2020 / Revised: 27 September 2020 / Accepted: 15 October 2020 / Published online: 29 October 2020 © The Author(s) 2020. This article is published with open access Abstract Bruton’s tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new drug approval. The first-in-class drug ibrutinib creates possibilities for an era of chemotherapy-free management of B-cell malignancies, and it is so popular that gross sales have rapidly grown to more than 230 billion dollars in just 6 years, with annual sales exceeding 80 billion dollars; it also became one of the five top-selling medicines in the world. Numerous clinical trials of BTK inhibitors in cancers were initiated in the last decade, and ~73 trials were intensively announced or updated with extended follow-up data in the most recent 3 years. In this review, we summarized the significant milestones in the preclinical discovery and clinical development of BTK inhibitors to better 1234567890();,: 1234567890();,: understand the clinical and commercial potential as well as the directions being taken. Furthermore, it also contributes impactful lessons regarding the discovery and development of other novel therapies. Introduction (DLBCL), follicular lymphoma (FL), multiple myeloma (MM), marginal zone lymphoma (MZL), mantle cell lym- B-cell malignancies include non-Hodgkin lymphomas phoma (MCL) and Waldenström’s macroglobulinemia (NHLs) and chronic lymphocytic leukaemia.
    [Show full text]
  • Comparison of Acalabrutinib, a Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells
    Author Manuscript Published OnlineFirst on December 29, 2016; DOI: 10.1158/1078-0432.CCR-16-1446 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells Viralkumar Patel,1 Kumudha Balakrishnan,1 Elena Bibikova3, Mary Ayres,1 Michael J. Keating,2 William G. Wierda,2 and Varsha Gandhi1,2 1Department of Experimental Therapeutics and 2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; and 3Acerta Pharma, Redwood City, CA. Correspondence: Varsha Gandhi, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 1950, 1901 East Road, Houston, TX 77054; Tel.: 713- 792-2989; Fax: 713-745-1710; e-mail: [email protected]. Conflict of Interest Disclosure: V.G. and W.G.W. received research and clinical trial funding from Acerta Pharma. E.B. is an employee of Acerta Pharma. The other authors do not have conflicts of interest. Running title: Acalabrutinib compared with ibrutinib in CLL cells Keywords: ibrutinib, acalabrutinib, chronic lymphocytic leukemia, apoptosis, Bruton tyrosine kinase Financial Support: This work was supported in part by grant CLL P01 CA81534 from the National Cancer Institute, by a Sponsored Research Agreement from Acerta Pharma, and by The University of Texas MD Anderson Cancer Center Moon Shot Program. MD Anderson Cancer Center is supported in part by the National Institutes of Health through Cancer Center Support Grant P30CA016672. Word count: Translational Relevance (113 words), Abstract (234 words), Text (3570 words) Figure and Table count: 6 figures; Reference count: 51; Supplementary data: 2 tables, 1 figure Scientific category: Cancer Therapy: Preclinical 1 Downloaded from clincancerres.aacrjournals.org on September 30, 2021.
    [Show full text]
  • Non-Hodgkin and Hodgkin Lymphoma: an Individualized Treatment Approach
    Non-Hodgkin and Hodgkin Lymphoma: An Individualized Treatment Approach Ann S. LaCasce, MD, MMSc 1 Presenter Disclosure Information The following relationships exist related to this presentation: Research to Practice: Speaker BMS: DSMB member Off Label/Investigational Discussion In accordance with Annenberg Center policy, faculty have been asked to disclose any discussion of unlabeled or unapproved use(s) of drugs or devices during the course of their presentations. 2 Diffuse Follicular large Mantle cell Hodgkin lymphoma B-cell lymphoma lymphoma lymphoma 3 Follicular lymphoma 4 Initial management of advanced stage follicular NHL What hasn’t changed: Newer options: Indications for therapy Obinutuzumab + chemo Rituximab plus lenalidomide Initial therapeutic options: Single agent rituximab Chemoimmunotherapy +/- maintenance 5 Bendamustine-R associated with improved PFS and toxicity compared to RCHOP without OS advantage in grade 1-2 FL n=279 Rummel et al. Lancet 2013 6 PRIMA Trial: maintenance R with improved PFS after R-chemo (95% R- CHOP/R-CVP), FL all grades Predated the use of bendamustine 7 Bachy et al. JCO 2019 Salles et al. Lancet 2011 Gallium: obinutuzumab associated with improved PFS but not OS Fatal AEs (infection, 2nd malignancies) more common with benda, during maintenance (R or O). Especially in patients > 70 y. Non-fatal AEs higher in the O arm (infections, cytopenias) Marcus et al. NEJM 2017 8 Relevance: R-chemo and R-lenalidomide plus maintenance with similar outcomes majority of patients received RCHOP Morschhauser et al. N Engl J Med 2018 9 Options for relapsed follicular lymphoma Older options: Newer options: Observation Lenalidomide + rituximab 200 cGY x 2 palliation PI3 kinase inhibitors Single agent rituximab Tazemetostat Chemoimmunotherapy Immunotherapies (CAR-T) 10 Augment: relapsed follicular lymphoma: lenalidomide + R with improved PFS compared with R alone Toxicity: R2 higher rates of neutropenia but infection rates similar.
    [Show full text]
  • Acalabrutinib Fact Sheet
    Acalabrutinib Fact Sheet (a KAL a broo ti nib) Generic Name: Acalabrutinib Trade Name: Calquence® from AstraZeneca Drug Type: Acalabrutinib is a targeted therapy. Targeted therapy is the result of years of research dedicated to understanding the differences between cancer cells and normal cells. Targeted therapies attack cancer cells while causing minimal damage to the normal cells, leading to fewer side effects. Each type of targeted therapy works a little differently, but all interfere with the ability of the cancer cell to grow, divide, repair and/or communicate with other cells. As a targeted therapy, acalabrutinib inhibits the function of Bruton’s tyrosine kinase (BTK). BTK is a protein inside the cell that may be overexpressed in malignant B-cells. The BTK-specific inhibitor, acalabrutinib, blocks BCR signaling and results in decreased malignant B-cell tumor growth and survival. What Conditions Are Treated by Acalabrutinib: Acalabrutinib is currently approved for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) by the US Food and Drug Administration (FDA) in collaboration with the Australian Therapeutic Goods Administration and Health Canada. In the United States, acalabrutinib is also approved for use in previously treated mantle cell lymphoma. The approval for treatment of CLL and SLL was based on studies that demonstrated that acalabrutinib as a single-agent therapy (and combination therapy with obinutuzumab for patients with previously untreated CLL), provides a significant improvement in tolerability as well as progression-free survival compared with standard treatment regimens for these diseases. Without specific FDA approval for treating WM, acalabrutinib prescribed for patients with WM is given “off-label,” signifying that the drug is being prescribed for an unapproved indication or in an unapproved age group, dosage, or route of administration.
    [Show full text]
  • Immunotherapies Shape the Treatment Landscape for Hematologic Malignancies Jane De Lartigue, Phd
    Feature Immunotherapies shape the treatment landscape for hematologic malignancies Jane de Lartigue, PhD he treatment landscape for hematologic of TIL therapy has been predominantly limited to malignancies is evolving faster than ever melanoma.1,3,4 before, with a range of available therapeutic Most recently, there has been a substantial buzz Toptions that is now almost as diverse as this group around the idea of genetically engineering T cells of tumors. Immunotherapy in particular is front and before they are reintroduced into the patient, to center in the battle to control these diseases. Here, increase their anti-tumor efficacy and minimize we describe the latest promising developments. damage to healthy tissue. This is achieved either by manipulating the antigen binding portion of the Exploiting T cells T-cell receptor to alter its specificity (TCR T cells) The treatment landscape for hematologic malig- or by generating artificial fusion receptors known as nancies is diverse, but one particular type of therapy chimeric antigen receptors (CAR T cells; Figure 1). has led the charge in improving patient outcomes. The former is limited by the need for the TCR to be Several features of hematologic malignancies may genetically matched to the patient’s immune type, make them particularly amenable to immunother- whereas the latter is more flexible in this regard and apy, including the fact that they are derived from has proved most successful. corrupt immune cells and come into constant con- CARs are formed by fusing part of the single- tact with other immune cells within the hemato- chain variable fragment of a monoclonal antibody poietic environment in which they reside.
    [Show full text]
  • Progression of a Solitary, Malignant Cutaneous Plasma-Cell Tumour to Multiple Myeloma in a Cat
    Case Report Progression of a solitary, malignant cutaneous plasma-cell tumour to multiple myeloma in a cat A. Radhakrishnan1, R. E. Risbon1, R. T. Patel1, B. Ruiz2 and C. A. Clifford3 1 Mathew J. Ryan Veterinary Hospital of the University of Pennsylvania, Philadelphia, PA, USA 2 Antech Diagnostics, Farmingdale, NY, USA 3 Red Bank Veterinary Hospital, Red Bank, NJ, USA Abstract An 11-year-old male domestic shorthair cat was examined because of a soft-tissue mass on the left tarsus previously diagnosed as a malignant extramedullary plasmacytoma. Findings of further diagnostic tests carried out to evaluate the patient for multiple myeloma were negative. Five Keywords hyperproteinaemia, months later, the cat developed clinical evidence of multiple myeloma based on positive Bence monoclonal gammopathy, Jones proteinuria, monoclonal gammopathy and circulating atypical plasma cells. This case multiple myeloma, pancytopenia, represents an unusual presentation for this disease and documents progression of an plasmacytoma extramedullary plasmacytoma to multiple myeloma in the cat. Introduction naemia, although it also can occur with IgG or IgA Plasma-cell neoplasms are rare in companion ani- hypersecretion (Matus & Leifer, 1985; Dorfman & mals. They represent less than 1% of all tumours in Dimski, 1992). Clinical signs of hyperviscosity dogs and are even less common in cats (Weber & include coagulopathy, neurologic signs (dementia Tebeau, 1998). Diseases represented in this category and ataxia), dilated retinal vessels, retinal haemor- of neoplasia include multiple myeloma (MM), rhage or detachment, and cardiomyopathy immunoglobulin M (IgM) macroglobulinaemia (Dorfman & Dimski, 1992; Forrester et al., 1992). and solitary plasmacytoma (Vail, 2001). These con- Coagulopathy can result from the M-component ditions can result in an excess secretion of Igs interfering with the normal function of platelets or (paraproteins or M-component) which produce a clotting factors.
    [Show full text]
  • Multiple Myeloma in Horses, Dogs and Cats: a Comparative Review Focused on Clinical Signs and Pathogenesis
    Chapter 15 Multiple Myeloma in Horses, Dogs and Cats: A Comparative Review Focused on Clinical Signs and Pathogenesis A. Muñoz, C. Riber, K. Satué, P. Trigo, M. Gómez-Díez and F.M. Castejón Additional information is available at the end of the chapter http://dx.doi.org/10.5772/54311 1. Introduction Multiple myeloma (MM) or plasma cell myeloma is a neoplastic proliferation of plasma cells that primarily involves the bone marrow but may originate from extramedullary sites [1-4]. Although it is uncommon in veterinary medicine, it has been reported in several species, in‐ cluding cats, dogs and, horses [1,3,5-10]. The frequency of MM in cats is slightly <1% of all malignant neoplasms. Canine MMs account for only 0.3% of all malignancies in dogs. MMs account approximately 2% of all hematopoietic neoplasms in both dogs and cats [4]. Most of the reports in the literature are limited to 1 to 16 case studies [4,11-16]. However, in a recent report regarding the incidence of bone disorders diagnosed in dogs, MM was the second most frequently diagnosed neoplastic condition in canine bone marrow [17]. Similarly, MM is an extremely rare disorder in horses. Ten cases, nine from the literature and a new case, were described by Edwards et al. [1] and only six additional cases have been described lastly [3,6-8,18]. Because of the uncommonly diagnosis of equine MM, the prevalence of this neoplasm is unknown in the horse. 2. Data of the patients with multiple myeloma MM is generally a disease of older animals, although some reports exist in young animals.
    [Show full text]
  • CALQUENCE (Acalabrutinib)
    CALQUENCE (acalabrutinib) RATIONALE FOR INCLUSION IN PA PROGRAM Background Calquence (acalabrutinib) is a small-molecule inhibitor of Bruton tyrosine kinase (BTK). Calquence and its active metabolite, ACP-5862, form a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B cell antigen receptor (BCR) and cytokine receptor pathways. In B cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. As a result of BTK inhibition, Calquence inhibits malignant B-cell proliferation and tumor growth (1). Regulatory Status FDA-approved indications: Calquence is a kinase inhibitor indicated for the treatment of adult patients with: (1) • Mantle cell lymphoma (MCL) who have received at least one prior therapy • Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) Calquence used in combination with obinutuzumab is only indicated for previously untreated CLL or SLL (1). Patients have a chance of Grade 3 or higher bleeding events (subdural hematoma, gastrointestinal bleeding, and hematuria). Calquence may increase the risk of hemorrhage in patients receiving antiplatelet or anticoagulant therapies. Consider the benefit-risk of withholding Calquence for at least 3 to 7 days pre and post-surgery depending upon the type of surgery and the risk of bleeding (1). Significant adverse reactions may occur with Calquence therapy including fatal and non-fatal infections, atrial fibrillation, atrial flutter, cytopenias, myelosuppression and primary malignancies including skin cancers. Patients should have the following monitored while on Calquence therapy: fever, infections, complete blood counts, and hydration (1).
    [Show full text]
  • Defining the Value of a Comparative Approach to Cancer Drug Development
    Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2347 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Defining the value of a comparative approach to cancer drug development 2 LeBlanc AK, Mazcko C, Khanna C. 3 Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, 4 National Institutes of Health, Bethesda, MD 20892. 5 Short title: Comparative Oncology in Drug Development 6 7 Abstract 8 Comparative oncology as a tool in drug development requires a deeper examination of the 9 value of the approach and examples of where this approach can satisfy unmet needs. This 10 review seeks to demonstrate types of drug development questions that are best answered 11 by the comparative oncology approach. We believe common perceived risks of the 12 comparative approach relate to uncertainty of how regulatory bodies will prioritize or 13 react to data generated from these unique studies conducted in diseased animals, and how 14 these new data will affect ongoing human clinical trials. We contend that it is reasonable to 15 consider these data as potentially informative and valuable to cancer drug development, 16 but as supplementary to conventional preclinical studies and human clinical trials 17 particularly as they relate to the identification of drug-associated adverse events. 18 19 Introduction 20 The study of naturally occurring cancer in companion animals, known as comparative 21 oncology, forms the basis of a translational drug development strategy that primarily 22 includes tumor-bearing pet dogs in clinical trials of novel cancer therapies destined for use 23 in human cancer patients.(1-5) The recognition of spontaneous cancer development in 1 Downloaded from clincancerres.aacrjournals.org on September 24, 2021.
    [Show full text]
  • Comparative Oncology
    INSTITUTIONAL RESEARCH Healthcare and Technology INDUSTRY NOTE Member FINRA/SIPC Toll Free: 866-928-0928 www.DawsonJames.com 1 N. Federal Highway, 5th floor Boca Raton, FL 33432 December 8, 2015 Comparative Oncology: A New “Breed” of Trial Sherry Grisewood, CFA Set to Improve Clinical Success in Oncology Managing Partner, Life Science Research 917-331-9963 sgrisewood @dawsonjames.com Summary Launching the Dawson James Comparative Biology and Veterinary Biotech Sector Universe Our research indicates that few of our peers are looking at companies who specifically are adopting comparative biology approaches to clinical development for new drugs or to veterinary biotechnology as an emerging subsector of the biotech world. We are introducing a universe of companies that fit a distinct profile for this new sector as many of the therapies being explored through comparative biology trials or under development in veterinary applications of biotechnology are truly transformative. As such, they may offer unique solutions in the treatment of cancer, neurological diseases, degenerative diseases such as osteoarthritis, rare diseases and in regenerative medicine. In coming weeks, we will expand on this initial universe of companies by adding various specialty “satellite” groups of companies to highlight selected therapeutic technologies, such as gene therapy, as well as bridging technologies and devices, such as imaging/visualization technologies, and molecular diagnostics that are being employed as enabling technologies by these companies. We will also feature selected indications, such as neuro-oncology, where these enabling technologies and comparative biology are coming together to offer potentially new treatment paradigms compared to traditional small molecule drug development. We believe that by identifying a suite of companies representative of this emerging sector, our investors may find potentially unique and undiscovered opportunities.
    [Show full text]
  • Leveraging Comparative Oncology to Maximize Translational Outcomes
    Leveraging Comparative Oncology to Maximize Translational Outcomes Cheryl London, DVM, PhD Research Professor, Tufts University Associated Faculty Professor, Ohio State University Consortium for Canine Comparative Oncology (C3O) Symposium Thomas Executive Conference Center, JB Duke Hotel February 17, 2017 High failure rate in oncology drug development Failure rate is not financially sustainable Amid flurry of new cancer drugs, how many offer real benefits? By Liz Szabo, Kaiser Health News Updated 4:01 AM ET Story highlights •Pushed by those who want earlier access to medications, FDA has approved a flurry of oncology drugs in recent years •A few have been home runs, allowing patients with limited life expectancies to live for years •But many more offer only marginal benefits, a researcher says Overall cancer survival has barely changed over the past decade. The 72 cancer therapies approved from 2002 to 2014 gave patients only 2.1 more months of life than older drugs, according to a study in JAMA Otolaryngology-Head & Neck Surgery. And those are the successes. Two-thirds of cancer drugs approved in the past two years have no evidence showing that they extend survival at all. The result: For every cancer patient who wins the lottery, there are many others who get little to no benefit from the latest drugs. Reasons for Failure Other 6% Financial 7% Safety 21% Efficacy 66% Most rodent models lack critical features of spontaneous neoplasia Many models use immunodeficient mice that lack key microenvironment components Cancer typically develops
    [Show full text]